Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.

Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.

Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.

PMID:
28382503
2.

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.

Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G.

Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20.

PMID:
26584689
3.

Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes.

Müller D, Borsi L, Stracke C, Stock S, Stollenwerk B.

Eur J Health Econ. 2015 Jun;16(5):517-27. doi: 10.1007/s10198-014-0605-5. Epub 2014 May 13.

PMID:
24818587
4.

Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.

Mortara L, Orecchia P, Castellani P, Borsi L, Carnemolla B, Balza E.

Cancer Med. 2013 Aug;2(4):478-87. doi: 10.1002/cam4.89. Epub 2013 May 29.

5.

Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.

Ventura E, Balza E, Borsi L, Tutolo G, Carnemolla B, Castellani P, Zardi L.

BMC Biotechnol. 2011 Nov 10;11:104. doi: 10.1186/1472-6750-11-104.

6.

Identification of a novel cell binding site of periostin involved in tumour growth.

Orecchia P, Conte R, Balza E, Castellani P, Borsi L, Zardi L, Mingari MC, Carnemolla B.

Eur J Cancer. 2011 Sep;47(14):2221-9. doi: 10.1016/j.ejca.2011.04.026. Epub 2011 May 24.

PMID:
21605971
7.

Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.

Crescenzi M, Persano L, Esposito G, Zulato E, Borsi L, Balza E, Ruol A, Ancona E, Indraccolo S, Amadori A.

Clin Cancer Res. 2011 Feb 1;17(3):447-58. doi: 10.1158/1078-0432.CCR-10-1420. Epub 2010 Nov 24.

8.

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Berndt A, Köllner R, Richter P, Franz M, Voigt A, Berndt A, Borsi L, Giavazzi R, Neri D, Kosmehl H.

Histochem Cell Biol. 2010 Apr;133(4):467-75. doi: 10.1007/s00418-010-0685-y. Epub 2010 Mar 17.

PMID:
20237793
9.

Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.

Ventura E, Sassi F, Parodi A, Balza E, Borsi L, Castellani P, Carnemolla B, Zardi L.

PLoS One. 2010 Feb 10;5(2):e9145. doi: 10.1371/journal.pone.0009145.

10.

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L.

Int J Cancer. 2010 Jul 1;127(1):101-10. doi: 10.1002/ijc.25018.

11.

Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.

Ventura E, Sassi F, Fossati S, Parodi A, Blalock W, Balza E, Castellani P, Borsi L, Carnemolla B, Zardi L.

J Biol Chem. 2009 Sep 25;284(39):26646-54. doi: 10.1074/jbc.M109.025924. Epub 2009 Jul 24.

12.

A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.

Balza E, Sassi F, Ventura E, Parodi A, Fossati S, Blalock W, Carnemolla B, Castellani P, Zardi L, Borsi L.

Int J Cancer. 2009 Aug 15;125(4):751-8. doi: 10.1002/ijc.24473. Erratum in: Int J Cancer. 2009 Nov 15;125(10):2487.

13.

B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A.

J Cancer Res Clin Oncol. 2009 Oct;135(10):1351-8. doi: 10.1007/s00432-009-0576-6. Epub 2009 Mar 27.

PMID:
19326143
14.

Reorganisation of the caecal extracellular matrix upon Salmonella infection--relation between bacterial invasiveness and expression of virulence genes.

Berndt A, Müller J, Borsi L, Kosmehl H, Methner U, Berndt A.

Vet Microbiol. 2009 Jan 1;133(1-2):123-37. doi: 10.1016/j.vetmic.2008.06.025. Epub 2008 Jul 4.

PMID:
18692970
15.

Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.

Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H, Berndt A, Janik T, Uecker A, Kiehntopf M, Böhmer FD.

Cardiovasc Res. 2008 Jul 1;79(1):118-26. doi: 10.1093/cvr/cvn063. Epub 2008 Mar 7.

PMID:
18326555
16.

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.

Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L, Neri D.

Int J Cancer. 2008 Jun 1;122(11):2405-13. doi: 10.1002/ijc.23408.

17.

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, De Lerma Barbaro A, Fossati S, Tosi G, Accolla RS, Borsi L.

Eur J Immunol. 2007 Dec;37(12):3381-92.

18.

A quantitative co-localization analysis of large unspliced tenascin-C(L) and laminin-5/gamma2-chain in basement membranes of oral squamous cell carcinoma by confocal laser scanning microscopy.

Franz M, Hansen T, Borsi L, Geier C, Hyckel P, Schleier P, Richter P, Altendorf-Hofmann A, Kosmehl H, Berndt A.

J Oral Pathol Med. 2007 Jan;36(1):6-11.

PMID:
17181735
19.

Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, Neri D, Kosmehl H.

J Cancer Res Clin Oncol. 2006 Aug;132(8):537-46. Epub 2006 May 31.

PMID:
16788848
20.

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L.

Clin Cancer Res. 2006 Apr 15;12(8):2575-82.

21.

Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front.

Franz M, Hansen T, Richter P, Borsi L, Böhmer FD, Hyckel P, Schleier P, Katenkamp D, Zardi L, Kosmehl H, Berndt A.

Histochem Cell Biol. 2006 Jul;126(1):125-31. Epub 2005 Dec 13.

PMID:
16344911
22.

Analysis of activated EGFR signalling pathways and their relation to laminin-5 gamma2 chain expression in oral squamous cell carcinoma (OSCC).

Richter P, Böhmer FD, Hindermann W, Borsi L, Hyckel P, Schleier P, Katenkamp D, Kosmehl H, Berndt A.

Histochem Cell Biol. 2005 Aug;124(2):151-60. Epub 2005 Sep 29.

PMID:
16052324
23.

Influence of various cytokines on adhesion and migration of the colorectal adenocarcinoma cell line HRT-18.

Köbel M, Budianto D, Schmitt WD, Borsi L, Siri A, Hauptmann S.

Oncology. 2005;68(1):33-9. Epub 2005 Mar 2.

PMID:
15809518
24.

mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma.

Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L, Kosmehl H.

J Pathol. 2004 Jul;203(3):771-9.

PMID:
15221936
25.

Differential in vivo and in vitro expression of ED-B+ fibronectin in adult human hematopoiesis.

Vogel W, Berndt A, Müller A, Dahse R, Haas KM, Borsi L, Zardi L, Kosmehl H.

Int J Mol Med. 2003 Dec;12(6):831-7.

PMID:
14612953
26.

Selective targeted delivery of TNFalpha to tumor blood vessels.

Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L.

Blood. 2003 Dec 15;102(13):4384-92. Epub 2003 Aug 21.

27.
28.

Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.

Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D.

Cancer Res. 2003 Jun 15;63(12):3202-10.

29.

Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis.

Kriegsmann J, Berndt A, Hansen T, Borsi L, Zardi L, Bräuer R, Petrow PK, Otto M, Kirkpatrick CJ, Gay S, Kosmehl H.

Rheumatol Int. 2004 Jan;24(1):25-33. Epub 2003 Apr 24.

PMID:
12712258
30.
31.

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.

Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P.

Clin Cancer Res. 2003 Feb;9(2):571-9.

32.

An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.

Melkko S, Halin C, Borsi L, Zardi L, Neri D.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1485-90.

PMID:
12459375
33.

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L.

Am J Pathol. 2002 Nov;161(5):1695-700.

34.

Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.

Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L.

Int J Cancer. 2002 Nov 1;102(1):75-85.

35.

Use of human recombinant antibodies to the marker of angiogenesis ed-b in cancer therapy.

Borsi L, Carnemolla B, Neri D, Zardi L.

Tumori. 2001 Nov-Dec;87(6):S8-10. Review. No abstract available.

PMID:
11989617
36.

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L.

Blood. 2002 Mar 1;99(5):1659-65.

37.
38.
39.

Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma.

Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H.

J Pathol. 1999 Dec;189(4):475-80.

PMID:
10629546
40.

Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma.

Kosmehl H, Berndt A, Strassburger S, Borsi L, Rousselle P, Mandel U, Hyckel P, Zardi L, Katenkamp D.

Br J Cancer. 1999 Nov;81(6):1071-9.

41.

A high-affinity human antibody that targets tumoral blood vessels.

Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L.

Blood. 1999 Jul 1;94(1):192-8.

42.

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L.

Am J Pathol. 1999 May;154(5):1345-52.

43.

Rat tenascin-R gene: structure, chromosome location and transcriptional activity of promoter and exon 1.

Leprini A, Gherzi R, Vecchi E, Borsi L, Zardi L, Siri A.

Cytogenet Cell Genet. 1998;83(1-2):115-23.

PMID:
9925948
44.

The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1.

Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G.

J Cell Biol. 1998 Aug 10;142(3):873-81.

45.

Preparation of phage antibodies to the ED-A domain of human fibronectin.

Borsi L, Castellani P, Allemanni G, Neri D, Zardi L.

Exp Cell Res. 1998 May 1;240(2):244-51.

PMID:
9596997
47.
48.

Human tenascin-R. Complete primary structure, pre-mRNA alternative splicing and gene localization on chromosome 1q23-q24.

Carnemolla B, Leprini A, Borsi L, Querzé G, Urbini S, Zardi L.

J Biol Chem. 1996 Apr 5;271(14):8157-60.

49.

Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms.

Hauptmann S, Zardi L, Siri A, Carnemolla B, Borsi L, Castellucci M, Klosterhalfen B, Hartung P, Weis J, Stöcker G, et al.

Lab Invest. 1995 Aug;73(2):172-82.

PMID:
7543628
50.

The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH.

Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L.

J Biol Chem. 1995 Mar 17;270(11):6243-5.

Supplemental Content

Support Center